All In Biotech

NDA 204958 · Chiesi

Kengreal

Cangrelor · Intravenous · P2Y12 Platelet Inhibitor

Novel

Last checked: Nov 20, 2026Latest source record: Jan 26, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Jun 22, 2015

Approved uses

1

Original approval plus efficacy supplements

Registered trials

30

4 Phase 3, 3 recruiting

FAERS reports

404

290 serious, 84 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 21, 2025.

KENGREAL is indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y 12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor [see Clinical Studies ( 14.1 )]. KENGREAL is a P2Y 12 platelet inhibitor indicated as an adjunct to percutaneous coronary intervention (PCI) for reducing the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients in who have not been treated with a P2Y 12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor. ( 1 )

Mechanism: Cangrelor is a direct P2Y 12 platelet receptor inhibitor that blocks ADP-induced platelet activation and aggregation. Cangrelor binds selectively and reversibly to the P2Y 12 receptor to prevent further signaling and platelet activation.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 22, 2015 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
1 products under this application
  • KENGREAL · CANGRELOR 50MG/VIAL · POWDER, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Cangrelor" as an intervention, any sponsor and status, largest first.

All 30 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use160
  • vascular stent thrombosis32
  • drug ineffective31
  • haemorrhage26
  • death22
  • no adverse event20
  • cardiac arrest18
  • inappropriate schedule of product administration18
  • cardiogenic shock15
  • gastrointestinal haemorrhage14
  • dyspnoea12
  • labelled drug-drug interaction medication error12

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20061
20072
20081
20111
20122
20138
20142
20157
201619
201729
201822
201946
202055
202118
202228
202340
202453
202548
202622

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 95 on PubMed

Sponsor: Chiesi

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.